Reoviruses

Jun 04, 2020

Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting the Induction of Rapid and Persistent Immune Responses With Systemic Pelareorep Treatment

May 26, 2020

Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer at the ESMO Breast Cancer Virtual Meeting

Mar 05, 2020

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights

Feb 28, 2020

Accidental T-cell Discovery Represents "A New Frontier" in Cancer Treatment

Feb 28, 2020

Accidental T-cell Discovery Represents "A New Frontier" in Cancer Treatment

Jan 27, 2020

Oncolytics Biotech® Announces Statistically Significant Data Identifying CEACAM6 as a Prospective Prognostic Biomarker for Pelareorep in the Treatment of Pancreatic Adenocarcinoma

Jan 21, 2020

Some U.S. Airports Begin Checking Passengers for a Deadly New Chinese Virus

Jan 13, 2020

Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma

Dec 04, 2017

Oncolytics Biotech® to Present at the Oncolytic Virotherapy Summit

Sep 19, 2017

Oncolytics Biotech® to Present at the Phacilitate Immuno-Oncology Frontiers Conference

Sep 18, 2017

Oncolytics Biotech® Announces Successful End-of-Phase 2 Meeting with FDA for REOLYSIN® in Metastatic Breast Cancer